In 2016, Kaseb et al. showed that higher GPC3 expression was associated with worse prognosis across BCLC stages [11], and in 2014, Xiao et al. demonstrated that GPC3 overexpression correlated with poor prognosis in HCC [16]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.